Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 3
1(16.7%)
Phase 4
1(16.7%)
6Total
Phase 1(4)
Phase 3(1)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04954989Phase 1Not Yet Recruiting

Biosimilarity Study of Intravenous Recombinant Human Erythropoietin in Healthy Volunteers

Role: lead

NCT06331715Phase 4Completed

Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

Role: lead

NCT06352138Phase 3Not Yet Recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products in Chronic Kidney Disease Patients

Role: lead

NCT04873765Phase 1Completed

Biosimilarity Study of Subcutaneous Pegfilgrastim in Healthy Volunteers

Role: lead

NCT04958772Phase 1Not Yet Recruiting

Biosimilarity Study of Subcutaneous Filgrastim in Healthy Volunteers

Role: lead

NCT06058689Phase 1Unknown

A Pilot Bioequivalence Study of Pomalidomide

Role: lead

All 6 trials loaded